Lupus (SLE): vizsgálatok itt: Kína
163 trials · From ClinicalTrials.gov, checked 2026. november 13.. Ask the study team whether a trial fits you.
- 1/2. fázisTaking peopleAnti-CD19 Chimeric Antigen Receptor T Cells for Refractory Systemic Lupus Erythematosus
- Where
- Beijing
- Életkor
- 3 év to 65 év
- People
- 18
- Run by
- Beijing GoBroad Hospital
See details and how to joinNCT06585514 - 1. fázisTaking peopleCT1190B in the Treatment of Patients With Moderate to Severe Refractory Systemic Lupus Erythematosus (SLE) or Refractory/Progressive Systemic Sclerosis (SSc)
- Where
- Beijing
- Életkor
- 18 év to 60 év
- People
- 27
- Run by
- Beijing GoBroad Hospital
See details and how to joinNCT06822881 - 1/2. fázisTaking peopleA Study of GR1803 in Systemic Lupus Erythematosus
- Where
- Wuhan
- Életkor
- 18 év to 60 év
- People
- 44
- Run by
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
See details and how to joinNCT07348055 - 1. fázisTaking peopleAn Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
- Where
- Bengbu
- Életkor
- 18 év to 65 év
- People
- 18
- Run by
- China Immunotech (Beijing) Biotechnology Co., Ltd.
See details and how to joinNCT07236762 - 1/2. fázisTaking peopleUmbilical Cord Blood CD19-BCMA CART Cell Therapy for SLE-LN, SSc, andpSS PAH.
- Where
- Beijing
- Életkor
- 6 év to 65 év
- People
- 45
- Run by
- Beijing GoBroad Hospital
See details and how to joinNCT06947473 - 1. fázisTaking peopleExploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases
- Where
- Xuzhou
- Életkor
- 18 év to 65 év
- People
- 18
- Run by
- China Immunotech (Beijing) Biotechnology Co., Ltd.
See details and how to joinNCT07236801 - 1. fázisTaking peopleA Clinical Study of Dual-Target, Universal CAR-T Cell Therapy for Refractory Systemic Lupus Erythematosus
- Where
- Beijing, Hefei, Wuhan
- Életkor
- 18 év to 65 év
- People
- 18
- Run by
- Hangzhou Qihan Biotech Co., Ltd.
See details and how to joinNCT07444307 - 1. fázisNot yet taking people in KínaYTS109 in Pediatric Relapsed/Refractory Autoimmune Diseases
- Where
- Shanghai
- Életkor
- 5 év to 18 év
- People
- 12
- Run by
- Children's Hospital of Fudan University
See details and how to joinNCT07439029 - Korai 1. fázisTaking peopleExploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases
- Where
- Shanghai
- Életkor
- 18 év to 70 év
- People
- 60
- Run by
- Changhai Hospital
See details and how to joinNCT07246096 - 1. fázisTaking peopleStudy of CD19 CAR-T Therapy for Refractory SLE
- Where
- Chongqing
- Életkor
- 5 év and over
- People
- 18
- Run by
- Chongqing Precision Biotech Co., Ltd
See details and how to joinNCT07403097 - 2. fázisNot yet taking people in KínaA Multicenter Phase 2a Clinical Study to Evaluate SIM0278 in Subjects With Active Lupus Nephritis
- Where
- Beijing
- Életkor
- 18 év to 75 év
- People
- 60
- Run by
- Simcere Pharmaceutical Co., Ltd
See details and how to joinNCT07393451 - 1/2. fázisTaking peopleStudy of YK012 in Moderate to Severe Systemic Lupus Erythematosus
- Where
- Beijing
- Életkor
- 18 év to 75 év
- People
- 189
- Run by
- Excyte Biopharma Ltd
See details and how to joinNCT07010835 - 1. fázisTaking peopleStudy of Ultra-Fast BCMA/CD70 CAR-T Therapy for Refractory SLE
- Where
- Nanjing
- Életkor
- 18 év and over
- People
- 18
- Run by
- Chongqing Precision Biotech Co., Ltd
See details and how to joinNCT07318259 - No phaseNot yet taking people in KínaA Prospective Comparative Study Involving Multiple Units to Evaluate the Efficacy and Safety of Telitacicept and Belimumab in the Treatment of Systemic Lupus Erythematosus.
- Where
- Jinan
- Életkor
- 18 év to 65 év
- People
- 180
- Run by
- Yipeng Liu
See details and how to joinNCT07069972 - 1. fázisTaking peopleA Study of LUCAR-G79D in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE) and Idiopathic Inflammatory Myopathies (r/r IIM)
- Where
- Bengbu, Changsha, Guangzhou, Nanchang, Xuzhou
- Életkor
- 18 év to 70 év
- People
- 38
- Run by
- Nanjing Legend Biotech Co.
See details and how to joinNCT07331272 - 1. fázisNot yet taking people in KínaThe Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HC022 Injection in Subjects With SLE/CLE
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 32
- Run by
- HC Biopharma Inc.
See details and how to joinNCT07306585 - 4. fázisTaking peopleEffects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease
- Where
- Wuhan
- Életkor
- 18 év to 80 év
- People
- 100
- Run by
- Tongji Hospital
See details and how to joinNCT07077486 - 1. fázisTaking peopleUB-VV410 in Subjects With Active Refractory Systemic Lupus Erythematosus or Lupus Nephritis
- Where
- Nanjing
- Életkor
- 18 év to 65 év
- People
- 21
- Run by
- Nanjing IASO Biotechnology Co., Ltd.
See details and how to joinNCT07109986 - 2. fázisTaking peopleStudy to Assess Efficacy and Safety of HSK39297 Tablets in Patients With LN
- Where
- Nanjing
- Életkor
- 18 év to 75 év
- People
- 105
- Run by
- Haisco Pharmaceutical Group Co., Ltd.
See details and how to joinNCT07363460 - 1. fázisNot yet taking people in KínaKN5501 Cell Injection for Refractory SLE(CLEAR)
- Where
- Beijing, Bengbu, Luoyang, Nanjing, Shanghai, Wuhan
- Életkor
- 18 év to 70 év
- People
- 36
- Run by
- Ruitherapeutics Co., LTD
See details and how to joinNCT07358988 - 1. fázisTaking peopleCAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases
- Where
- Tianjin
- Életkor
- 18 év and over
- People
- 12
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07315087 - No phaseTaking peopleImmune Profiling of Refractory cSLE Exposed to CD3×CD19 BiTE
- Where
- Hangzhou
- Életkor
- 5 év and over
- People
- 6
- Run by
- The Children's Hospital of Zhejiang University School of Medicine
See details and how to joinNCT07352332 - Korai 1. fázisTaking peopleA Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Dynamics of Universal CD19 / 20 Car-t Cell Injection in Moderate to Severe Refractory Systemic Lupus Erythematosus
- Where
- Wuhan
- Életkor
- 18 év to 65 év
- People
- 12
- Run by
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
See details and how to joinNCT07339332 - 1. fázisTaking peopleStudy of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE
- Where
- Nanjing
- Életkor
- 18 év and over
- People
- 18
- Run by
- Chongqing Precision Biotech Co., Ltd
See details and how to joinNCT07331467 - No phaseNot yet taking people in KínaACE1831 in Adult Subjects With Relapsed/Refractory Systemic Lupus Erythematosus （SLE）
- Where
- Wuhan
- Életkor
- 18 év to 60 év
- People
- 22
- Run by
- Tongji Hospital
See details and how to joinNCT07314567